Oryzon Genomics S.A.
Develops epigenetic-based medicines for cancer and central nervous system disorders.
ORY | MC
Overview
Corporate Details
- ISIN(s):
- ES0167733015
- LEI:
- 95980063R15RDF29DK13
- Country:
- Spain
- Address:
- Sant Ferran 74, 08940 Cornellà de Llobregat
- Website:
- https://www.oryzon.com/en
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company and a European leader in the development of epigenetics-based therapeutics. The company leverages its proprietary epigenetic platform to discover, develop, and commercialize innovative, personalized medicines for patients with cancer and central nervous system (CNS) disorders. Its approach focuses on identifying and validating biomarkers and therapeutic targets to create advanced therapies, with a pipeline that includes the development of LSD1 inhibitors for psychiatric and neurodegenerative diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-10 00:00 |
Pre-Annual General Meeting Information
Convocatoria de la Junta General Extraordinaria de accionistas de Oryzon Genomi…
|
Spanish | 182.7 KB | ||
| 2025-06-27 00:00 |
Post-Annual General Meeting Information
ORYZON anuncia los resultados de la votación de su Junta General Ordinaria de A…
|
Spanish | 44.3 KB | ||
| 2025-05-26 08:04 |
Pre-Annual General Meeting Information
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S…
|
Spanish | 139.0 KB | ||
| 2025-05-26 00:00 |
Pre-Annual General Meeting Information
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S…
|
Spanish | 139.0 KB | ||
| 2025-05-12 07:52 |
Earnings Release
La sociedad remite información sobre los resultados del primer trimestre de 2025
|
Spanish | 370.8 KB | ||
| 2025-05-08 08:06 |
Regulatory News Service
ORYZON recibe una ayuda no reembolsable de 13,26 millones de € para su proyecto…
|
Spanish | 250.1 KB | ||
| 2025-04-29 00:00 |
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
|
Spanish | 91.4 KB | ||
| 2025-04-25 13:52 |
Declaration of Voting Results & Voting Rights Announcements
Se comunica la inscripción en el Registro mercantil de la escritura de ampliaci…
|
Spanish | 202.4 KB | ||
| 2025-04-24 08:13 |
Share Issue/Capital Change
Resultado de la colocación acelerada
|
Spanish | 178.7 KB | ||
| 2025-04-23 18:34 |
Share Issue/Capital Change
Lanzamiento de ampliación de capital acelerada
|
Spanish | 195.2 KB | ||
| 2025-04-23 17:58 |
Share Issue/Capital Change
Lanzamiento de ampliación de capital acelerada
|
Spanish | 195.2 KB | ||
| 2025-02-28 14:54 |
Post-Annual General Meeting Information
ORYZON anuncia los resultados de la votación de su Junta General Extraordinaria…
|
Spanish | 51.6 KB | ||
| 2025-02-28 00:00 |
Post-Annual General Meeting Information
ORYZON anuncia los resultados de la votación de su Junta General Extraordinaria…
|
Spanish | 55.0 KB | ||
| 2025-02-27 19:03 |
Remuneration Information
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del …
|
Spanish | 189.1 KB | ||
| 2025-02-27 18:57 |
Governance Information
La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2024
|
Spanish | 437.0 KB |
Automate Your Workflow. Get a real-time feed of all Oryzon Genomics S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oryzon Genomics S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oryzon Genomics S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
